Diagnostic Imaging’s Weekly Scan: January 18 — January 24

Welcome to Diagnostic Imaging’s Weekly Scan, which offers an opportunity to catch up on the most well-viewed radiology content of the past week.

In a new prospective multicenter comparison study, researchers found that the 2023 version of the American Association for the Study of Liver Diseases (AASLD) system for hepatocellular carcinoma (HCC) surveillance provided a 94 percent sensitivity in contrast to 76 percent for the AASLD v2018 criteria and 60 percent for the US LI-RADS v2017 system.

In a recent interview, Manisha Bahl, M.D., discussed recent research demonstrating a significant decline in the sensitivity of digital breast tomosynthesis (DBT) with increasing breast density as well as challenges in the utilization of supplemental imaging for women with dense breasts.

Here is a clip from the interview.

A prospective research comparison of ultra-low-dose (ULD) PCCT and low-dose (LD) PCCT protocols yielded comparable image quality and strong agreement on emphysema severity assessments with ULD PCCT offering significantly reduced radiation dosing.

In another recent interview with Diagnostic Imaging, David Yankelevitz, M.D., discussed the recent FDA clearance of the AI-CVD multisystem screening software and the ongoing evolution of incorporating computed tomography into personalized screening and risk assessments.

Here is a clip from the interview.

In a new seven-study meta-analysis with a total of 493 cases involving high-risk breast lesions, researchers found that contrast-enhanced breast MRI did not miss any cases of invasive breast cancer.

Thank you for checking out the latest edition of Diagnostic Imaging’s Weekly Scan.